UCB's Global Corporate Website
Welcome to UCB in the United States
  • Healthcare Professionals
  • Patients
  • Investors

    • Categories

    Archives

    Mar

    17

    Exploring the future of dermatology at AAD 2023

    Read More Share:linkedin| twitter| email| facebook

    Mar

    16

    You Speak, We Listen: How Community Voices Drive Our Work in HS

    Read More Share:linkedin| twitter| email| facebook

    Mar

    16

    UCB to Present Eight Bimekizumab Abstracts at AAD 2023 with Results from Studies in Psoriasis, Psoriatic Arthritis, and Hidradenitis Suppurativa

    Read More Share:linkedin| twitter| email| facebook

    Mar

    15

    Building a Community of Trust in Epilepsy & Rare Syndromes

    Read More Share:linkedin| twitter| email| facebook

    Feb

    17

    Patient-First, Patient-Focused: Our Purpose and Promise

    Read More Share:linkedin| twitter| email| facebook

    Jan

    20

    Employee Spotlight: Ian Crassweller – Leading and Evolving Through Change

    Read More Share:linkedin| twitter| email| facebook

    Jan

    18

    Annals of the Rheumatic Diseases Publishes Results from Two Bimekizumab Phase 3 Studies in Axial Spondyloarthritis

    Read More Share:linkedin| twitter| email| facebook

    Jan

    06

    UCB announces rozanolixizumab BLA for the treatment of generalized myasthenia gravis filed with U.S. FDA and designated for Priority Review

    Read More Share:linkedin| twitter| email| facebook

    Dec

    23

    UCB Announces FDA Acceptance of BLA Resubmission for Bimekizumab

    Read More Share:linkedin| twitter| email| facebook

    Dec

    13

    Employee Spotlight: Leah VanderVeen and Her Time as a Court Appointed Special Advocate for Foster Children

    Read More Share:linkedin| twitter| email| facebook

    © 2009 - 2025 UCB, Inc. Atlanta. All rights reserved. 
    Last updated: August 2025